Literature DB >> 21593240

Measurement of functional anti-meningococcal serogroup a activity using strain 3125 as the target strain for serum bactericidal assay.

Jan T Poolman1, Isabel De Vleeschauwer, Nathalie Durant, Nathalie Devos, Christiane Feron, Pascal Lestrate, Vincent Weynants, Dominique Boutriau.   

Abstract

Functional anti-N. meningitidis serogroup A (MenA) activity in human serum is detected by serum bactericidal assay (SBA), using either rabbit (rSBA) or human (hSBA) complement, with F8238 as the recommended MenA SBA target strain. However, the F8238 strain may not be optimal for this purpose because, as we show here, it expresses the L11 immunotype, whereas most MenA invasive strains express the L(3,7)9 or L10 immunotype. Moreover, SBA results may be strain dependent, because immunotypes differ in their sensitivity to complement, emphasizing the need to choose the most appropriate strain. Sera from random subsets of infants, toddlers, children, and adolescents in clinical trials of MenA conjugate vaccines were tested by rSBA using strains 3125 (L10) and F8238 (L11). In unvaccinated subjects from all age groups, the percentages of seropositive samples (rSBA-MenA titer, ≥1:8) was lower using strain 3125 than using strain F8238. However, in toddlers and adolescents immunized with a conjugate MenA vaccine, the percentages of seropositive samples generally were similar using either strain in the rSBA. In two studies, sera also were tested with hSBA. Using hSBA, the differences in the percentages of seroprotective samples (hSBA-MenA titer, ≥1:4) between strains 3125 and F8238 was less apparent, and in contrast with rSBA, the percentage of seroprotective samples from unvaccinated subjects was slightly higher using strain 3125 than using strain F8238. In adults vaccinated with plain MenA polysaccharide, the percentage of seroprotective samples was higher using strain 3125 than with strain F8238, and the vaccine response rates using strain 3125 were better aligned with the demonstrated efficacy of MenA vaccination. In conclusion, SBA results obtained using the MenA L10 3125 strain better reflected vaccine-induced immunity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21593240      PMCID: PMC3147334          DOI: 10.1128/CVI.00549-10

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  29 in total

Review 1.  Neisseria meningitidis serogroup B: laboratory correlates of protection.

Authors:  Clementien Vermont; Germie van den Dobbelsteen
Journal:  FEMS Immunol Med Microbiol       Date:  2002-10-11

2.  Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.

Authors:  R Borrow; N Andrews; D Goldblatt; E Miller
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

3.  Primary vaccination with a new heptavalent DTPw-HBV/Hib-Neisseria meningitidis serogroups A and C combined vaccine is well tolerated.

Authors:  Angkool Kerdpanich; Boonyarat Warachit; Pensri Kosuwon; Salvacion R Gatchalian; Veerachai Watanaveeradej; Thitiporn Borkird; Pope Kosalaraksa; Htay-Htay Han; Yanee Hutagalung; Dominique Boutriau; Kurt Dobbelaere
Journal:  Int J Infect Dis       Date:  2007-08-22       Impact factor: 3.623

4.  The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.

Authors:  S Gatchalian; E Palestroque; I De Vleeschauwer; H H Han; J Poolman; L Schuerman; K Dobbelaere; D Boutriau
Journal:  Int J Infect Dis       Date:  2007-11-05       Impact factor: 3.623

5.  A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children.

Authors:  M Knuf; D Kieninger-Baum; P Habermehl; P Muttonen; H Maurer; P Vink; J Poolman; D Boutriau
Journal:  Vaccine       Date:  2009-11-01       Impact factor: 3.641

6.  Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.

Authors:  Dan M Granoff; Jo Anne Welsch; Sanjay Ram
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

7.  Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.

Authors:  Lisa A Jackson; Roger Baxter; Keith Reisinger; Annette Karsten; Jina Shah; Lisa Bedell; Peter M Dull
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079

8.  Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years.

Authors:  Lars Ostergaard; Edouard Lebacq; Jan Poolman; Gudrun Maechler; Dominique Boutriau
Journal:  Vaccine       Date:  2008-10-01       Impact factor: 3.641

9.  A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents.

Authors:  Lisa A Jackson; Robert M Jacobson; Keith S Reisinger; Alessandra Anemona; Lisa E Danzig; Peter M Dull
Journal:  Pediatr Infect Dis J       Date:  2009-02       Impact factor: 2.129

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  7 in total

1.  Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.

Authors:  Rolando Pajon; Andrew M Fergus; Oliver Koeberling; Dominique A Caugant; Dan M Granoff
Journal:  PLoS Negl Trop Dis       Date:  2011-09-06

2.  Molecular signatures of antibody responses derived from a systems biology study of five human vaccines.

Authors:  Shuzhao Li; Nadine Rouphael; Sai Duraisingham; Sandra Romero-Steiner; Scott Presnell; Carl Davis; Daniel S Schmidt; Scott E Johnson; Andrea Milton; Gowrisankar Rajam; Sudhir Kasturi; George M Carlone; Charlie Quinn; Damien Chaussabel; A Karolina Palucka; Mark J Mulligan; Rafi Ahmed; David S Stephens; Helder I Nakaya; Bali Pulendran
Journal:  Nat Immunol       Date:  2013-12-15       Impact factor: 25.606

Review 3.  A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines.

Authors:  Jamie Findlow; Paul Balmer; Ray Borrow
Journal:  Hum Vaccin Immunother       Date:  2019-04-23       Impact factor: 3.452

4.  Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults.

Authors:  Javier Díez-Domingo; Juan Carlos Tinoco; Airi Poder; Ener Cagri Dinleyici; Haylene Nell; Ignacio Salamanca de la Cueva; Tolga Ince; Edson Duarte Moreira; Khatija Ahmed; Kleber Luz; Yulia Kovshirina; Carlos Eduardo Medina Pech; Tauseefullah Akhund; Valerio Romolini; Marco Costantini; Thembile Mzolo; Barry Kunnel; Isabelle Lechevin; Marianna Aggravi; Paola Tiberi; K Narendran; Juan-Antonio García-Martínez; Venere Basile; Elena Fragapane; Maria Lattanzi; Michele Pellegrini
Journal:  Hum Vaccin Immunother       Date:  2021-10-06       Impact factor: 3.452

5.  Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers.

Authors:  Timo Vesikari; Aino Forstén; Dominique Boutriau; Véronique Bianco; Marie Van der Wielen; Jacqueline M Miller
Journal:  Hum Vaccin Immunother       Date:  2012-10-02       Impact factor: 3.452

6.  Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008.

Authors:  Caroline L Trotter; Seydou Yaro; Berthe-Marie Njanpop-Lafourcade; Aly Drabo; Sita S Kroman; Regina S Idohou; Oumarou Sanou; Leah Bowen; Helen Findlow; Serge Diagbouga; Bradford D Gessner; Ray Borrow; Judith E Mueller
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

7.  Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso.

Authors:  Haoua Tall; Seydou Yaro; Hervé B N Kpoda; Soumeya Ouangraoua; Caroline L Trotter; Berthe-Marie Njanpop Lafourcade; Helen Findlow; Xilian Bai; Catherine Martin; Ikenna Nwakamma; Jean Bosco Ouedraogo; Bradford D Gessner; Ray Borrow; Judith E Mueller
Journal:  Clin Infect Dis       Date:  2015-11-15       Impact factor: 9.079

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.